HANSOH PHARMA (03692.HK): Almonertinib Wins Positive CHMP Opinion for EU Approval in NSCLC

On 15 Nov 2026, HANSOH PHARMA (03692.HK) said CHMP recommended EU approval of almonertinib for non-small cell lung cancer.

NewTimeSpace News: On 15 November 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 3692) published a voluntary announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026 recommending the granting of a marketing authorisation for almonertinib, marketed outside China as Aumseqa®, for the treatment of non-small cell lung cancer.

The marketing authorisation remains subject to final approval by the European Commission. The Company had previously published announcements on 27 September and 11 October 2026 on the status of the EU marketing authorisation.

The Company advised shareholders and potential investors to exercise caution when dealing in its shares.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.